Blood thinner safety study for heart stent patients
Part of Heart & circulation clinical trials.
This trial tests ways to improve safety for people with high bleeding risk who take blood thinners after getting a heart stent. It aims to find better quality checks to prevent bleeding and clotting problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with acute coronary syndrome (a serious heart condition) and received a drug-coated heart stent.
- You must have a high risk of bleeding based on a special checklist used by doctors.
- You must be able to complete a score calculation called OPT-CAD.
- Your doctor must think you can take two blood thinners (aspirin plus clopidogrel or ticagrelor) for at least 12 months.
- You must not be allergic to aspirin, clopidogrel, or ticagrelor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter, lower dose of two blood thinners is safe and effective for patients with a recent heart attack or unstable angina who are at high risk for bleeding. It uses a special stent that might allow for less medication.
This study tests whether a personalized score (OPT-CAD) can help decide the best time to stop or reduce blood-thinning medication in people who have had a heart attack and a stent placed. It aims to balance preventing future heart issues while lowering the risk of bleeding.
This trial tests a special stent designed for people who have a high risk of bleeding. It aims to see if using this stent with a shorter treatment of blood thinners can be safe and effective for heart artery procedures.
This trial studies which blood-thinner (antiplatelet) strategy is safest and most effective for people at high risk of bleeding after a procedure called PCI. It also looks at longer-term outcomes and whether adjusting treatment can improve safety without losing heart protection.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
Hear when a new Acute Coronary Syndrome (ACS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.